BLA 021536 · Novo Nordisk INC
Levemir Flextouch
Insulin Detemir Recombinant · Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Dec 8, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 16, 2005
Approved uses
4
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 9, 2024.
LEVEMIR is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use LEVEMIR is not recommended for the treatment of diabetic ketoacidosis. LEVEMIR is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ). Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis.
Mechanism: The primary activity of insulin, including LEVEMIR, is regulation of glucose metabolism. Insulins and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 2012 Supplement 41 · Efficacy LabelLetter
- Apr 27, 2012 Supplement 39 · Efficacy LabelLetter
- Mar 29, 2012 Supplement 37 · Efficacy LabelLetter
- Jun 16, 2005 Original approval · Type 1 - New Molecular Entity NovelLetterReviewLabel
5 products under this application
- LEVEMIR FLEXTOUCH · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- LEVEMIR INNOLET · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
- LEVEMIR · INSULIN DETEMIR RECOMBINANT 1000 UNITS/10ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- LEVEMIR PENFILL · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
- LEVEMIR FLEXPEN · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Detemir Recombinant" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Levemir (Insulin Detemir)
2024 spending
$30.6M
Beneficiaries
48,292
142,657 claims
Per beneficiary
$634
$10.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $436,907,523 |
| 2021 | $373,910,077 |
| 2022 | $319,727,025 |
| 2023 | $287,253,250 |
| 2024 | $30,621,217 |
Part D: Levemir Flexpen (Insulin Detemir)
2024 spending
$121M
Beneficiaries
210,817
559,470 claims
Per beneficiary
$575
$10.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,025,556,477 |
| 2024 | $121,306,539 |
Part D: Levemir Flextouch (Insulin Detemir)
2024 spending
$957K
Beneficiaries
3,073
5,655 claims
Per beneficiary
$311
$10.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,554,791,325 |
| 2021 | $1,495,189,258 |
| 2022 | $1,408,211,049 |
| 2023 | $184,280,489 |
| 2024 | $956,769 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Novo Nordisk · Also marketed as Levemir Innolet, Levemir, Levemir Penfill, Levemir Flexpen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.